A new model for estimation of significant fibrosis in primary care. SAFE to use?

Affiliations

Editorial

Hannes Hagström. Hepatology. 2023.

. 2023 Jan 1;77(1):18-19.

doi: 10.1002/hep.32549. Epub 2022 May 21.

¹ Department of Medicine , Huddinge, Karolinska Institutet , Stockholm , Sweden.

No abstract available

Comment on

The steatosis-associated fibrosis estimator (SAFE) score: A tool to detect low-risk NAFLD in primary care.
Sripongpun P, Kim WR, Mannalithara A, Charu V, Vidovszky A, Asch S, Desai M, Kim SH, Kwong AJ. Sripongpun P, et al. Hepatology. 2023 Jan 1;77(1):256-267. doi: 10.1002/hep.32545. Epub 2022 May 24. Hepatology. 2023. PMID: 35477908 Free PMC article.

1. Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015;313(22):2263–73.
1. Taylor RS, Taylor RJ, Bayliss S, Hagström H, Nasr P, Schattenberg JM, et al. Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta‐analysis. Gastroenterology. 2020;158(6):1611–25.e12.
1. Hagström H, Nasr P, Ekstedt M, Hammar U, Stål P, Hultcrantz R, et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy‐proven NAFLD. J Hepatol. 2017;67(6):1265–73.
1. Brunt EM, Clouston AD, Goodman Z, Guy C, Kleiner DE, Lackner C, et al. Complexity of ballooned hepatocyte feature recognition: defining a training atlas for artificial intelligence‐based imaging in NAFLD. J Hepatol. 2022;76(5):1030–41.
1. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313–21.